ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1883

Temporal Patterns of Cardiometabolic Comorbidities Before and After Psoriatic Arthritis Diagnosis: A Nationwide Retrospective Study from Poland.

Batko Bogdan1, Mateusz Szeląg2, Krzysztof Batko3, Magdalena Krajewska-Włodarczyk4, Zbigniew Żuber5, Marcin Stajszczyk6, Brygida Kwiatkowska7 and Tomasz Guzik8, 1Department of Rheumatology and Immunology, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski University, Krakow, Poland, Kraków, Poland, 2Ministry of Health, Warsaw, Poland, 3Department of Dermatology, University Hospital in Krakow, Poland, Krakow, Poland, 4University of Warmia & Mazury, Olsztyn, Poland, 5Department of Pediatrics, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski University, Krakow, Poland, Krakow, Poland, 6Department of Rheumatology and Autoimmune Diseases, Silesian Center for Rheumatology, Orthopedics and Rehabilitation, Ustroń, Poland, Ustron, Poland, 7Clinic of Early Arthritis, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland, Warsaw, Poland, 8BHF Centre for Research Excellence, Centre for Cardiovascular Sciences, The University of Edin-burgh, Edinburgh, UK, Edinburgh, United Kingdom

Meeting: ACR Convergence 2025

Keywords: Administrative Data, Cardiovascular, Comorbidity, Epidemiology, Psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (1877–1913) Epidemiology & Public Health Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: While the association between psoriatic arthritis (PsA) and cardiometabolic disorders is established, the temporal sequence and progression of these comorbidities remain poorly characterized. To examine the temporal relationship between psoriatic arthritis (PsA) and cardiometabolic disorders by comparing their prevalence patterns before and after PsA diagnosis.

Methods: This nationwide retrospective case-control study analyzed Polish National Health Fund claims data (2011–2021). We identified 3,391 incident PsA patients diagnosed in 2016 using a definition requiring either: ICD-10 codes (M07.0-M07.3, L40.5) plus DMARD prescriptions, or ≥3 encounters with these codes in rheumatology settings. Cases were matched 1:10 to population controls by age, sex, and region. Cardiometabolic conditions (including hypertension, diabetes, ischemic heart disease, and metabolic disorders) were assessed based on ≥2 recorded diagnoses during five-year periods before and after PsA diagnosis.

Results: PsA patients demonstrated significantly elevated cardiometabolic risk both before and after diagnosis. Prevalence ratios (PR) were consistently higher across multiple conditions, with slight increases observed following diagnosis: hypertensive diseases (pre-PR 1.05 [95% CI 1.03–1.06] to post-PR 1.06 [1.04–1.07]), diabetes mellitus (pre-PR 1.05 [1.03–1.07] to post-PR 1.06 [1.04–1.08]), and ischemic heart diseases (pre-PR 1.04 [1.02–1.06] to post-PR 1.05 [1.03–1.07]). Notably, obesity showed the highest relative risk (pre-PR 1.13 [1.04–1.24] to post-PR 1.20 [1.09–1.32]). The mean cardiometabolic burden per patient increased by 34% following PsA diagnosis (from 0.32 to 0.43 conditions), with marked increases in heart failure (154%), lipoprotein disorders (50%), and diabetes (46%).

Conclusion: Temporal patterns in comorbidity of cardiovascular significance support the concept of shared inflammatory and metabolic pathways underlying these associations, highlighting the need for early cardiometabolic risk assessment and intervention in PsA management.

Supporting image 1Temporal risk of various cardiometabolic disorders in patients with incident psoriatic arthritis as compared to the general population

Supporting image 2Heatmap for the overall burden of common cardiometabolic disorders in incident psoriatic arthritis patients and the general population

Supporting image 3Temporal change in the burden of various cardiometabolic disorders in the five years after psoriatic arthritis diagnosis, as compared to the general population.


Disclosures: B. Bogdan: AbbVie/Abbott, 2, 6, Amgen, 2, 5, 6, Boehringer-Ingelheim, 2, 6, Bristol-Myers Squibb(BMS), 1, 6, Celgene, 1, 6, Eli Lilly, 1, 4, 5, GlaxoSmithKlein(GSK), 1, 6, Janssen, 1, 6, Novartis, 1, 5, 6, Roche, 1, 6, UCB, 1, 6; M. Szeląg: None; K. Batko: None; M. Krajewska-Włodarczyk: AbbVie/Abbott, 6, Eli Lilly, 6, Pfizer, 6, Roche, 6, UCB, 6; Z. Żuber: AbbVie/Abbott, 6, Eli Lilly, 6, Novartis, 6, Pfizer, 6, Roche, 6, UCB, 6; M. Stajszczyk: AbbVie/Abbott, 6, Novartis, 6, Pfizer, 6, Roche, 6, UCB, 6; B. Kwiatkowska: AbbVie/Abbott, 6, Novartis, 6, Pfizer, 6, Roche, 6, UCB, 6; T. Guzik: AbbVie/Abbott, 6, Novartis, 6, Pfizer, 6, Roche, 6, UCB, 6.

To cite this abstract in AMA style:

Bogdan B, Szeląg M, Batko K, Krajewska-Włodarczyk M, Żuber Z, Stajszczyk M, Kwiatkowska B, Guzik T. Temporal Patterns of Cardiometabolic Comorbidities Before and After Psoriatic Arthritis Diagnosis: A Nationwide Retrospective Study from Poland. [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/temporal-patterns-of-cardiometabolic-comorbidities-before-and-after-psoriatic-arthritis-diagnosis-a-nationwide-retrospective-study-from-poland/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/temporal-patterns-of-cardiometabolic-comorbidities-before-and-after-psoriatic-arthritis-diagnosis-a-nationwide-retrospective-study-from-poland/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology